Overview

The Effect of Fluvastatin XL® Treatment in Patients With Metabolic Syndrome

Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
This study evaluated safety, tolerability and efficacy of Fluvastatin XL® -extended release (80 mg once daily) in patients with metabolic syndrome
Phase:
Phase 4
Details
Lead Sponsor:
Novartis
Treatments:
Fluvastatin